Tyrosine Kinase Inhibitors Used Alone or in Combination to Treat RCC

Video

Transcript:

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
A panel of 5 experts on renal cell carcinoma
Chandler H. Park, MD, an expert on renal cell carcinoma
Benjamin Garmezy, MD
Samer A. Srour, MB ChB, MS
Wenxin (Vincent) Xu, MD,
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Elizabeth Plimack, MD, MS, FASCO, an expert on bladder cancer
Related Content
Scott Kopetz, MD, PhD, The University of Texas MD Anderson Cancer Center

Insider Insights: Unveiling Takeaways from AACR 2024

April 11th 2024
Article
Neal Shore, MD, FACS

FDA Approval Insights: Nadofaragene Firadenovec in BCG-Unresponsive NMIBC

January 26th 2023
Podcast
Samer A. Srour, MB ChB, MS

CTX130 Provides Disease Control and Manageable Safety in Advanced ccRCC

April 8th 2024
Article
Kyle A. Blum, MD, MS

Blum Highlights Implications of CA-125 Levels in Renal Medullary Carcinoma

December 19th 2022
Podcast
John McGrane, MD, consultant oncologist, Royal Cornwall Hospitals NHS Trust

NICE Endorses Cabozantinib Plus Nivolumab in Advanced RCC

April 2nd 2024
Article
Durvalumab Plus Guadecitabine in ccRCC | Image Credit: © Nitiphol - stock.adobe.com

Durvalumab Plus Guadecitabine Shows PFS Benefit in Cohort of Patients With ccRCC

April 1st 2024
Article